During the corresponding time, Omeros Corporation recorded a revenue increase by 387.1 % year on year, sequentially revenue fell by -51.86 %. While revenue at the Omeros Corporation's corporate clients
Omeros's Comment on Sales, Marketing and Customers
The company develops therapies targeting complement-mediated diseases, cancers, and addictive or compulsive disorders, focusing on the lectin and alternative complement pathways. Its commercial product, YARTEMLEA (narsoplimab-wuug), is approved for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in patients aged two years and older. YARTEMLEA, a selective MASP-2 inhibitor, has been commercially available since January 2026. A marketing authorization application for YARTEMLEA in TA-TMA is under review by the European Medicines Agency. The company also has a partnered program for Zaltenibart (OMS906), a MASP-3 inhibitor with potential applications in paroxysmal nocturnal hemoglobinuria (PNH), renal diseases including immunoglobulin A nephropathy (IgAN), C3 glomerulopathy, atypical hemolytic uremic syndrome, and other immune and complement-driven disorders. Novo Nordisk Healthcare AG holds exclusive global rights to develop and commercialize Zaltenibart under an agreement finalized in November 2025.
Omeros Corporation s investigational compound, Zaltenibart (OMS906), has entered an advanced stage of clinical evaluation for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), with the activation of clinical trial sites now underway. As a novel inhibitor of MASP-3, an essential activator in the complement alternative pathway, Zaltenibart presents a promising therapeutic option designed to address both intravascular and extravascular hemolysis. This article aims to elucidate the significance of the Phase 3 program and the potential transformations it may herald in the management of PNH. Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disorder characterized by complement-mediated int...
In recent developments within the pharmaceutical sector, Omeros Corporation has made significant strides in the treatment of complement-mediated disorders. The company has updated its ongoing Phase 3 clinical trial program for Zaltenibart (OMS906), an investigational drug designed to inhibit MASP-3, a critical activator of the alternative complement pathway. This pathway plays a pivotal role in paroxysmal nocturnal hemoglobinuria (PNH), a severe hematologic condition characterized by intravascular hemolysis, which leads to hemoglobinuria, thrombosis, and an increased risk of renal failure.As of now, clinical trial site activation for patient enrollment in the Zaltenibart program is underway, indicating Omero...
Omeros Corporation s Recent Developments in TA-TMA TreatmentOmeros Corporation, a Seattle-based biopharmaceutical company, has recently generated significant buzz within the medical and investment communities by announcing critical advancements related to their investigational drug, narsoplimab. As a first-in-class monoclonal antibody targeting the mannan-binding lectin serine protease-2 (MASP-2), narsoplimab has been under intensive scrutiny due to its potential efficacy in treating thrombotic microangiopathy (TMA) caused by hematopoietic stem cell transplants. Key Announcements and PresentationsOmeros is set to present outcomes from its Expanded Access Program during the upcoming 2025 Tandem Meetings, ho...
Omeros Corporation: Navigating Breakthroughs and Financial Landscapes in 2024 A Dual Focus on Financial Performance and Clinical ProgressIn a year marked by both fiscal focus and groundbreaking clinical milestones, Omeros Corporation (NASDAQ: OMER) unveiled crucial updates and forward-looking insights pertaining to its financial performance and groundbreaking research developments. The company s efforts, intricately tied to its robust pipeline and strategic financial management, are pivotal to the biopharmaceutical landscape. First Quarter Financial Results and Conference CallOmeros Corporation has scheduled the release of its financial results for the first quarter ending on March 31, 2024. These results w...
Omeros Corporation Strengthens Balance Sheet and Extends Debt Maturity into 2028Seattle-based biopharmaceutical company, Omeros Corporation, has recently announced a series of strategic financial transactions that not only strengthen its balance sheet but also extend the maturity profile on a significant portion of its debt. These moves provide the company with a secure source of capital while also supporting potential commercialization efforts for its lectin pathway inhibitor, narsoplimab. With these transactions, Omeros gains the flexibility to manage the remaining balance of its 2026 convertible notes.Omeros Corporation, listed on the Nasdaq stock exchange under the ticker symbol OMER, has successfully co...
In an announcement made today, Omeros Corporation (NASDAQ: OMER) revealed that it will be sharing its financial results for the first quarter and year ended March 31, 2024, on Wednesday, May 15, 2024, after the market closes. As a prominent biopharmaceutical company, Omeros Corporation is known for its innovation and development of therapeutics to treat various medical conditions. This article summarizes the key facts and highlights related to the announcement.Financial Disclosure and Conference Call Details:Hosted by Omeros management, a conference call and live webcast will be held on May 15, 2024, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and delve into recent dev...
Omeros’s Comment on Sales, Marketing and Customers
The company develops therapies targeting complement-mediated diseases, cancers, and addictive or compulsive disorders, focusing on the lectin and alternative complement pathways. Its commercial product, YARTEMLEA (narsoplimab-wuug), is approved for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in patients aged two years and older. YARTEMLEA, a selective MASP-2 inhibitor, has been commercially available since January 2026. A marketing authorization application for YARTEMLEA in TA-TMA is under review by the European Medicines Agency. The company also has a partnered program for Zaltenibart (OMS906), a MASP-3 inhibitor with potential applications in paroxysmal nocturnal hemoglobinuria (PNH), renal diseases including immunoglobulin A nephropathy (IgAN), C3 glomerulopathy, atypical hemolytic uremic syndrome, and other immune and complement-driven disorders. Novo Nordisk Healthcare AG holds exclusive global rights to develop and commercialize Zaltenibart under an agreement finalized in November 2025.
Sources:
Omeros Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Omeros Corporation’s corporate clients.
For your research, we’ve provided 9 tables on Omeros Corporation corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
0.75 %